Vanguard Group Inc Ikena Oncology, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,532,169 shares of IKNA stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,532,169

Previous 1,524,848 0.48%

Holding current value

$2.57 Million

Previous $3 Million 27.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.27 - $2.0 $9,297 - $14,642	7,321 Added 0.48%	1,532,169 $2.18 Million
Q4 2023 Feb 14, 2024	BUY	$1.33 - $4.4 $228,579 - $756,201	171,864 Added 12.7%	1,524,848 $3 Million
Q3 2023 Nov 14, 2023	BUY	$4.09 - $6.43 $1.05 Million - $1.66 Million	257,814 Added 23.54%	1,352,984 $5.86 Million
Q2 2023 Aug 14, 2023	BUY	$3.5 - $7.31 $338,037 - $706,014	96,582 Added 9.67%	1,095,170 $7.18 Million
Q1 2023 May 15, 2023	BUY	$2.62 - $4.97 $49,966 - $94,782	19,071 Added 1.95%	998,588 $3.45 Million

Q4 2022 Feb 10, 2023	BUY	$2.0 - $2.89 $1,028 - $1,485	514 Added 0.05%	979,517 $2.61 Million
Q3 2022 Nov 14, 2022	BUY	$3.46 - $6.0 $1.05 Million - $1.83 Million	304,898 Added 45.23%	979,003 $3.48 Million
Q2 2022 Aug 12, 2022	SELL	$3.23 - $7.4 $374,337 - $857,615	-115,894 Reduced 14.67%	674,105 $2.99 Million
Q1 2022 May 13, 2022	BUY	$5.61 - $13.85 $42,664 - $105,329	7,605 Added 0.97%	789,999 $4.82 Million
Q4 2021 Feb 14, 2022	BUY	$10.52 - $16.96 $1.7 Million - $2.74 Million	161,708 Added 26.05%	782,394 $9.81 Million
Q3 2021 Nov 12, 2021	BUY	$9.82 - $15.23 $2.87 Million - $4.45 Million	292,074 Added 88.88%	620,686 $7.83 Million
Q2 2021 Aug 13, 2021	BUY	$13.27 - $26.0 $4.36 Million - $8.54 Million	328,612 New	328,612 $4.61 Million

Others Institutions Holding IKNA

# of Institutions

Shares Held

32M

Call Options Held

Put Options Held

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $60.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Ikena Oncology, Inc. Transaction History